Merck partners with Variational AI
Sarah Braner · C&EN Global Enterprise · 2024
Merck & Co. has partnered with Variational AI to explore using artificial intelligence in drug discovery. Variational AI CEO Handol Kim says Merck will test Variational’s Enki platform in finding new small molecules, though the firms did not identify specific targets. This platform, which Kim has compared to DALL-E and Midjourney, is meant to generate small-molecule structures in response to a target product profile.